[go: up one dir, main page]

WO2010131035A8 - Novel crystalline polymorph of sitagliptin dihydrogen phosphate - Google Patents

Novel crystalline polymorph of sitagliptin dihydrogen phosphate Download PDF

Info

Publication number
WO2010131035A8
WO2010131035A8 PCT/GB2010/050772 GB2010050772W WO2010131035A8 WO 2010131035 A8 WO2010131035 A8 WO 2010131035A8 GB 2010050772 W GB2010050772 W GB 2010050772W WO 2010131035 A8 WO2010131035 A8 WO 2010131035A8
Authority
WO
WIPO (PCT)
Prior art keywords
dihydrogen phosphate
crystalline polymorph
novel crystalline
sitagliptin dihydrogen
sitagliptin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2010/050772
Other languages
French (fr)
Other versions
WO2010131035A1 (en
Inventor
Vinayak Govind Gore
Maheshkumar Gadakar
Priyanka Bhosle
Suresh Shinde
Prashant Yadav
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Mylan Pharmaceuticals Pvt Ltd
Original Assignee
Generics UK Ltd
Mylan India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics UK Ltd, Mylan India Pvt Ltd filed Critical Generics UK Ltd
Priority to CA2759196A priority Critical patent/CA2759196A1/en
Publication of WO2010131035A1 publication Critical patent/WO2010131035A1/en
Publication of WO2010131035A8 publication Critical patent/WO2010131035A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a novel anhydrous crystalline form of sitagliptin dihydrogenphosphate (I), to processes for its preparation and to its use in pharmaceutical compositions.
PCT/GB2010/050772 2009-05-11 2010-05-11 Novel crystalline polymorph of sitagliptin dihydrogen phosphate Ceased WO2010131035A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2759196A CA2759196A1 (en) 2009-05-11 2010-05-11 Novel crystalline polymorph of sitagliptin dihydrogen phosphate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN723/KOL/2009 2009-05-11
IN723KO2009 2009-05-11

Publications (2)

Publication Number Publication Date
WO2010131035A1 WO2010131035A1 (en) 2010-11-18
WO2010131035A8 true WO2010131035A8 (en) 2011-10-06

Family

ID=42288585

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/050772 Ceased WO2010131035A1 (en) 2009-05-11 2010-05-11 Novel crystalline polymorph of sitagliptin dihydrogen phosphate

Country Status (2)

Country Link
CA (1) CA2759196A1 (en)
WO (1) WO2010131035A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846916B2 (en) 2009-05-11 2014-09-30 Generics [Uk] Limited Sitagliptin synthesis
WO2012131005A1 (en) 2011-03-29 2012-10-04 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition of sitagliptin
SI2736909T1 (en) 2011-07-27 2017-08-31 Farma Grs, D.O.O. Process for the preparation of sitagliptin and its pharmaceutically acceptable salts
EP3046562A1 (en) * 2013-09-20 2016-07-27 Unilever N.V. Anti-diabetic composition
CZ27898U1 (en) 2015-01-13 2015-03-02 Zentiva, K.S. Crystalline modification 2 (3R) -3-Amino-1- [3- (trifluoromethyl) -6,8-dihydro-5H- [1,2,4,] triazolo [4,3-a] pyrazine-7 L-tartrate -yl] -4- (2,4,5-trifluorophenyl) butan-1-one
CZ27930U1 (en) 2015-01-13 2015-03-10 Zentiva, K.S. Crystalline modification of 3 L-tartrate (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2625B1 (en) * 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
AU2004268024B2 (en) * 2003-09-02 2007-07-12 Merck Sharp & Dohme Llc Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US20070021430A1 (en) * 2003-09-23 2007-01-25 Chen Alex M Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
US20090247532A1 (en) * 2008-03-28 2009-10-01 Mae De Ltd. Crystalline polymorph of sitagliptin phosphate and its preparation
WO2010032264A2 (en) * 2008-08-27 2010-03-25 Cadila Healthcare Limited Improved process for preparation of (2r)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin- 7(8h)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine & new impurities in preparation thereof

Also Published As

Publication number Publication date
CA2759196A1 (en) 2010-11-18
WO2010131035A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
WO2010092090A3 (en) Novel salts of sitagliptin
WO2014014835A3 (en) Criystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
WO2010139979A3 (en) Processes for preparing crystalline forms of dasatinib
WO2011093825A3 (en) Effervescent dosage forms comprising cephalosporin antibiotic
WO2011012816A3 (en) Pharmaceutical formulation
GEP20156328B (en) Solid pharmaceutical compositions and processes for their production
EA029539B8 (en) Pharmaceutical composition of sitagliptin
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
WO2010139981A3 (en) Processes for preparing crystalline forms of dasatinib
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
WO2008083130A3 (en) Amorphous and crystalline form a of carvedilol phosphate
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
WO2010131035A8 (en) Novel crystalline polymorph of sitagliptin dihydrogen phosphate
WO2011015882A3 (en) Anhydrate of triotropium bromide
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
WO2010049449A3 (en) Novel salts of sunitinib
WO2008001201A3 (en) Pharmaceutical compositions of clopidogrel
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2010070677A3 (en) A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof
WO2013128379A3 (en) Crystalline polymorphic forms of linagliptin
WO2012038979A3 (en) A process for preparation of ertapenem
WO2010079045A3 (en) Crystalline salt forms of flibanserine
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
WO2012019428A8 (en) Benzohydrol derivatives, a preparation process and pharmaceutical use thereof
WO2011045774A3 (en) Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10720192

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2759196

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 8328/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2012510372

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 10720192

Country of ref document: EP

Kind code of ref document: A1